Llwytho...
Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites
BACKGROUND: Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneo...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Curr Oncol |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Multimed Inc.
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209563/ https://ncbi.nlm.nih.gov/pubmed/30464679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4231 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|